

IN THE CLAIMS:

Cancel Claims 1-13 without prejudice and substitute therefor the following Claims 14-33:

Claims 1-13. Canceled

14. (New) Use of Hypericum perforatum (St. John's wart) and/or Ginko biloba (gingko) and/or Crocus Sativus (saffron) and/or Panax ginseng (ginseng) for the production of a medicament for the treatment of schizophrenia.

15. (New) Use according to claim 14, wherein the plant, plant parts, dried plant or plant parts, extracts, extract fractions, pure substances and their derivatives and the salts of the plant are used.

16. (New) Use according to claim 14, wherein the extract used is an alcoholic, alcoholic-aqueous extract with primary, secondary and tertiary alcohols of the series C1 to C5, preferably methanol and ethanol, in the composition of alcohol/water of between 100/0 to 30/70, preferably 80/20 to 50/50.

17. (New) Use according to claim 16, wherein there are produced in a one- and multi-step production process.

18. (New) Use according to claim 14, wherein the St. John's wart extract used has the following amounts of components: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

19. (New) Use according to claim 14, wherein the ginkgo extract has the following amounts and components: 20 - 30% by weight flavone glycosides, together with 2 - 8% of ginkgolides, particularly preferred 23 to 27% flavone glycosides and 5 to 7 % by weight ginkgolides.

20. (New) Use according to claim 14, wherein the saffron extract comprises the components α -, β -pinene, 1, 8 cineol, crocin, picrocrocin as well as optionally the degradation product thereof safranal, particularly preferred in the following concentrations: 5 - 10% pinene and cineol, 4 - 10% picrocrocin and/or 2-6% safranal.

21. (New) Use according to claim 14, wherein the ginseng root extract comprises the components, inter alia, triterpene saponines (ginsenosides/ginsenoids), sesquiterpenes and polyacetylenes, particularly preferred in the following concentrations: 3 - 9% ginsenoids.

22. (New) Use according to claim 14, wherein use occurs in the form of liquid, semi-solid and solid forms of administration, in particular solutions, suspensions, tablets, film-coated tablets, dragees, capsules, effervescent tablets, effervescent granulate, chew tablets and suppositories.

23. (New) Use according to claim 14, wherein the case of St. John's wart extract, the daily dose of the extracts is 300 to 2700 mg in up to 3 separate doses per day, preferably 750 - 1500 mg in 1 - 2 separate doses per day.

24. (New) Use according to claim 14, wherein in the case of ginkgo biloba, *Crocis sativus* and *Panax ginseng*, the daily dose of the extracts is 50 mg - 1000 mg of extract.

25. (New) Combination preparation containing St. John's wart, ginkgo, saffron and/or ginseng in addition to, as further components, a psychotherapeutic drug against schizophrenia for the simultaneous, separate or graduated use in the treatment of schizophrenia.

26. (New) Use according to claim 14, in add-on therapy in combination with psychotherapeutic drugs for treating schizophrenia, in particular neuroleptics, in particular of the group of classic neuroleptics such as haloperidol, benperidol, chlorprotixene, flupentixol, fluphenazine, perazine, perphenazine, thioridazine, atypical neuroleptics, in particular clozapine, olanzapine, seroquel, sertindole, as well as other psychotherapeutic drugs suitable for treating schizophrenia.

27. (New) Use according to claim 15, wherein the extract used is an alcoholic, alcoholic-aqueous extract with primary, secondary and tertiary alcohols of the series C1 to C5, preferably methanol and ethanol, in the composition of alcohol/water of between 100/0 to 30/70, preferably 80/20 to 50/50.

28. (New) Use according to claim 27, wherein there are produced in a one- and multi-step production process.

29. (New) Use according to claim 15, wherein the St. John's wart extract used has the following amounts of components: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

30. (New) Use according to claim 16, wherein the St. John's wart extract used has the following amounts of components: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

31. (New) Use according to claim 17, wherein the St. John's wart extract used has the following amounts of components: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

32. (New) Use according to claim 27, wherein the St. John's wart extract used has the following amounts of components: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.

33. (New) Use according to claim 28, wherein the St. John's wart extract used has the following amounts of components: 0.01 - 2% hypericins, 0.01 - 30% hyperforins, 2-35% flavonoids, preferably 0.10 to 0.40% hypericins and 1 - 6% hyperforins.